

SEL Ophthalmology Pathways Outcomes and Monitoring Framework for Medical Retinal Treatment for Wet Age-Related Macular Degeneration (wet AMD), Diabetic Macular Oedema (DMO) and Retinal Vein Occlusion (RVO)

Measures:

KPI	Intervention	Target/ Standard	Measure	Data Source	Who Measures	Frequency of reporting (in any financial year)
1.	Audit of best value treatment choice for naïve patients with wet AMD, DMO and RVO (aflibercept 2mg or ranibizumab)	90% of new initiations for intravitreal treatment to follow the relevant local SEL pathway choices and use the best value intravitreal treatment	<p>(x) the number of new starter patients initiated on a first line intravitreal treatment as outlined in the pathway for wet AMD, DMO and RVO</p> <p>(y) the total number of new starter patients initiated on intravitreal treatment for wet AMD, DMO and RVO</p> <p>$[x/y] \times 100$ = the percentage of new starter patients initiated on a first line intravitreal treatment for wet AMD, DMO and RVO*</p> <ul style="list-style-type: none"> For anti-VEGFs, to also capture data on treat and extend injection intervals reached with aflibercept 2mg or ranibizumab for AMD, DMO and RVO. <p>*Reasons for deviating from the local SEL pathway choices and preferred best value intravitreal treatment to be outlined</p>	Trust database	Trusts	Annual (snapshot audit – quarterly review of data)** **Audit data to represent an even split between wet AMD, DMO and RVO.
2.	<p>Audit of treatment against non-mandated NICE criteria/local commissioning elements:</p> <p>i) Audit on patients being initiated</p>	100% of patients to comply with the relevant local SEL pathway	<p>Audit to demonstrate:</p> <ol style="list-style-type: none"> Total number of patients initiated on treatment Compliance with pathway including the criteria for treating under this section of the pathway (100%)* Number of patients who have achieved optimal response as outlined in the relevant pathway Frequency of treatment 	Trust database	Trusts	Annual

Not to be used for commercial or marketing purposes. Strictly for use within the NHS

	<p>on treatment with evidence of late AMD (wet active) and visual acuity better than 6/12)</p> <p>ii) Audit on patients being initiated on treatment with central retinal thickness less than 400 microns for DMO.</p> <p>iii) Audit on patients receiving off-label dexamethasone intravitreal implant for DMO or RVO (4 monthly)</p> <p>iv) Audit on patients receiving off-label dexamethasone intravitreal implant for DMO (more than 7 implants)</p>		<p>e) Number of patients stopped (and broad themes on reasons)</p> <p>*Reasons for deviating from the local SEL pathway choices and preferred best value biologic to be outlined</p>			
--	---	--	--	--	--	--

Not to be used for commercial or marketing purposes. Strictly for use within the NHS

3.	Audit on patients initiated on treatment with aflibercept 8mg (for wet AMD or DMO) or faricimab intravitreal injections (for wet AMD, DMO or RVO)	100% of patients to comply with the local SEL pathway	<p>Audit to demonstrate:</p> <ul style="list-style-type: none"> a) The number of patients initiated on treatment with aflibercept 8mg intravitreal injections b) The number of patients initiated on treatment with faricimab intravitreal injections c) Compliance with the relevant pathway including the criteria for treating* d) Number of patients who have achieved optimal response in line with the relevant pathway e) Number of patients on aflibercept 8mg or faricimab achieving treat and extend intervals greater than 12 weeks f) Number of patients stopped (and broad themes on reasons) <p>*Reasons for deviating from the local SEL pathway choices to be outlined</p>	Trust database	Trusts	<p>Annual (snapshot audit – quarterly review of data)**</p> <p>**Audit data to represent an even split between wet AMD, DMO and RVO.</p>
4.	Measure impact of the pathway on overall service commissioning costs to ensure value for money	High-Cost drugs use (biologics) in SEL	Breakdown of biologic use and cost by indication at regular intervals by Trust, for SEL ICB	Acute activity (finance reporting)	SEL ICB (Business Intelligence + Trust high-cost drug reporting)	Quarterly

Approved by:

SEL Ophthalmology pathway group: January 2026

SEL Integrated Medicines Optimisation Committee: March 2026

Review date: March 2027 (or sooner if indicated)

References:

1. National Institute for Health and Care Excellence (NICE), *Age-related macular degeneration. NICE guideline [NG82]*. 2018. <https://www.nice.org.uk/guidance/ng82> [Accessed July 2025]
2. National Institute for Health and Care Excellence (NICE), *Diabetic retinopathy: management and monitoring [NG242]*. 2024. [Overview](#) | [Diabetic retinopathy: management and monitoring](#) | [Guidance](#) | [NICE](#) [Accessed December 2025]

Not to be used for commercial or marketing purposes. Strictly for use within the NHS

South East London Integrated Medicines Optimisation Committee (SEL IMOC). A partnership between NHS organisations in South East London Integrated Care System: NHS South East London (covering the boroughs of Bexley/Bromley/Greenwich/ Lambeth/Lewisham and Southwark) and GSTFT/KCH /SLaM/ Oxleas NHS Foundation Trusts and Lewisham & Greenwich NHS Trust